158 related articles for article (PubMed ID: 18062724)
1. Darunavir: in the treatment of HIV-1 infection.
Fenton C; Perry CM
Drugs; 2007; 67(18):2791-801. PubMed ID: 18062724
[TBL] [Abstract][Full Text] [Related]
2. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
[TBL] [Abstract][Full Text] [Related]
4. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
Katlama C; Esposito R; Gatell JM; Goffard JC; Grinsztejn B; Pozniak A; Rockstroh J; Stoehr A; Vetter N; Yeni P; Parys W; Vangeneugden T;
AIDS; 2007 Feb; 21(4):395-402. PubMed ID: 17301557
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
[TBL] [Abstract][Full Text] [Related]
7. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
Arastéh K; Clumeck N; Pozniak A; Lazzarin A; De Meyer S; Muller H; Peeters M; Rinehart A; Lefebvre E;
AIDS; 2005 Jun; 19(9):943-7. PubMed ID: 15905675
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M; Miralles D; Hill A
HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
[TBL] [Abstract][Full Text] [Related]
9. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Hill A; Moyle G
HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
[TBL] [Abstract][Full Text] [Related]
10. Darunavir: in treatment-experienced pediatric patients with HIV-1 infection.
McKeage K; Scott LJ
Paediatr Drugs; 2010 Apr; 12(2):123-31. PubMed ID: 20218748
[TBL] [Abstract][Full Text] [Related]
11. [Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Arazo Garcés P; Omiste Sanvicente T
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():23-31. PubMed ID: 19195456
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
Molina JM; Cohen C; Katlama C; Grinsztejn B; Timerman A; Pedro Rde J; Vangeneugden T; Miralles D; Meyer SD; Parys W; Lefebvre E; ;
J Acquir Immune Defic Syndr; 2007 Sep; 46(1):24-31. PubMed ID: 17621237
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
Arastéh K; Yeni P; Pozniak A; Grinsztejn B; Jayaweera D; Roberts A; Hoy J; De Meyer S; Vangeneugden T; Tomaka F
Antivir Ther; 2009; 14(6):859-64. PubMed ID: 19812449
[TBL] [Abstract][Full Text] [Related]
14. Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.
Robertson J; Feinberg J
Expert Opin Pharmacother; 2012 Jun; 13(9):1363-75. PubMed ID: 22594781
[TBL] [Abstract][Full Text] [Related]
15. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
16. Darunavir (TMC114): a new HIV-1 protease inhibitor.
Molina JM; Hill A
Expert Opin Pharmacother; 2007 Aug; 8(12):1951-64. PubMed ID: 17696796
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
Rachlis A; Clotet B; Baxter J; Murphy R; Lefebvre E
HIV Clin Trials; 2007; 8(4):213-20. PubMed ID: 17720661
[TBL] [Abstract][Full Text] [Related]
18. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F
Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
[TBL] [Abstract][Full Text] [Related]
20. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
